| Description | Fobrepodacin (SPR720) is an orally active and potent phosphate prodrug of SPR719 (VXc-486). Fobrepodacin has potent bactericidal activities in vivo. |
| In vivo | Fobrepodacin (oral gavage; 10, 30, 100 mg/kg; once per day; 5 times per week for 4 weeks) reduces the mycobacterial burden in a model of chronic tuberculosis infection in mice[1]. Fobrepodacin (oral; 100 mg/kg; once per day; 5 days per week, for 8 weeks) improves the bactericidal activities of antimycobacterial drugs[1]. Animal Model: Six-week old female BALB/c and C57BL/6 mice uninfected or M. tuberculosis-infected (Erdman)[1]Dosage: 10, 30, 100 mg/kg Administration: Oral gavage; once per day; 5 times per week for 4 weeks Result: Reduced the mycobacterial burden in a model of chronic tuberculosis infection in mice. |
| Synonyms | SPR720, pVXc-486 |
| molecular weight | 508.447 |
| Molecular formula | C21H26FN6O6P |
| CAS | 1384984-31-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Locher CP, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.Antimicrob Agents Chemother. 2015 Mar;59(3):1455-65. |